Bile acid malabsorption explained

Bile acid diarrhea / Bile acid malabsorption
Synonyms:Bile acid-induced diarrhea, cholerheic or choleretic enteropathy, bile salt diarrhea, bile salt malabsorption
Field:Gastroenterology
Symptoms:Bowel movement frequency, soft or watery stools, diarrhea, urgency
Complications:Anxiety, fecal incontinence
Onset:Any age
Duration:Chronic (longlasting, persistent)
Types:Primary or secondary or types 1, 2 and 3
Causes:Surgical resection of ileum, cholecystectomy, idiopathic
Risks:Pelvic radiation disease, small intestinal bacterial overgrowth
Diagnosis:Fecal bile acids, SeHCAT, 7α-hydroxy-4-cholesten-3-one
Differential:Irritable bowel syndrome, microscopic colitis
Medication:Bile acid sequestrants
Prognosis:Good with treatment
Frequency:1 in 100 of population
Deaths:Non-fatal

Bile acid malabsorption (BAM), known also as bile acid diarrhea, is a cause of several gut-related problems, the main one being chronic diarrhea. It has also been called bile acid-induced diarrhea, cholerheic or choleretic enteropathy, bile salt diarrhea or bile salt malabsorption. It can result from malabsorption secondary to gastrointestinal disease, or be a primary disorder, associated with excessive bile acid production. Treatment with bile acid sequestrants is often effective. It is recognised as a disability in the United Kingdom under the Equality Act 2010.

Signs and symptoms

A persistent (chronic) history of diarrhea, with watery or mushy, unformed stools, (types 6 and 7 on the Bristol stool scale), sometimes with steatorrhea, increased frequency and urgency of defecation are common manifestations, often with fecal incontinence and other gastrointestinal symptoms such as abdominal swelling, bloating and abdominal pain.[1] [2] [3] [4]

People with this disorder often report impairments of mental health and well-being, including fatigue, dizziness, anxiety about leaving home (primarily due to fear of fecal incontinence), depression, one survey reports. It contributes in delays in diagnosis.

Pathogenesis

Enterohepatic circulation of bile salts

Bile acids (also called bile salts) are produced in the liver, secreted into the biliary system, stored in the gallbladder and are released after meals stimulated by cholecystokinin. They are important for the digestion and absorption of fats (lipids) in the small intestine. Usually over 95% of the bile acids are absorbed in the terminal ileum and are taken up by the liver and resecreted. This enterohepatic circulation of bile acids takes place 4–6 times in 24 hours and usually less than 0.5 g of bile acids enter the large intestine per 24 h. When larger amounts of bile acids enter the large intestine, they stimulate water secretion and intestinal motility in the colon, which causes symptoms of chronic diarrhea.[5]

Intestinal absorption of bile acids

The ileum is very efficient at absorbing the glyco- and taurine-conjugated forms of the bile salts. The apical sodium-dependent bile salt transporter (ASBT, IBAT, gene symbol SLC10A2) is the first step in absorption at the brush-border membrane. The cytoplasmic ileal bile acid binding protein (IBABP, ILBP, gene symbol FABP6) and the basolateral heterodimer of OSTα and OSTβ transfer bile acids through and out of the cell where they eventually enter the portal vein. These bile acid transporters are all highly expressed in the ileum but not in the liver, jejunum or colon.[6] When expression of these specialized transporters is reduced, the intestine is less efficient at bile acid reabsorption (Type 1 bile acid malabsorption). If intestinal motility is affected by gastro-intestinal surgery, or bile acids are deconjugated by small intestinal bacterial overgrowth, absorption is less efficient (Type 3 bile acid malabsorption). A very small proportion of the patients with no obvious disease (Type 2 bile acid malabsorption) may have mutations in ASBT,[7] but this mutation is not more common in most patients and does not affect function.[8]

Overproduction of bile acids

Primary bile acid diarrhea (Type 2 bile acid "malabsorption") may be caused by an overproduction of bile acids.[9] Several groups of workers have failed to show any defect in ileal bile acid absorption in these patients, and they have an enlarged bile acid pool, rather than the reduced pool expected with malabsorption.[10] The synthesis of bile acids in the liver is negatively regulated by the ileal hormone fibroblast growth factor 19 (FGF19), and lower levels of this hormone result in overproduction of bile acids, which are more than the ileum can absorb.[9]

Dysmetabolism and gut microbiome

A study found that patients suffering from bile acid diarrhea are characterized by a dysmetabolic and prediabetic-like profile, with higher postprandial concentrations of glucose, insulin and glucagon, compared with matched healthy controls.[11] The underlying mechanisms are not fully understood. Furthermore, gut microbiome composition differs from that of people who do not suffer from bile acid diarrhea.[12] [13] [14]

Diagnosis

Several methods have been developed to identify the disorder but there are difficulties with all of them.[15] Diagnosis of bile acid malabsorption is easily and reliably made by the SeHCAT test. This nuclear medicine test involves two scans a week apart and so measures multiple cycles of bile acid excretion and reabsorption. There is limited radiation exposure (0.3 mSv). Retention of SeHCAT at 7 days is normally above 15%; values less than 15%, 10% and 5% predict respectively mild, moderate and severe abnormal retention and an increasing likelihood of response to bile acid sequestrants.[16] This test is not licensed in the USA, and is underutilized even where it is available.[17] [18] Older methods such as the 14C-glycocholic breath test are no longer in routine clinical use.

Measurement of 7α-Hydroxy-4-cholesten-3-one, (C4), a bile acid precursor, in serum, shows the increased bile acid synthesis found in bile acid malabsorption.[19] This test is an alternative diagnostic means when available. Fasting blood FGF19 values may have value in the recognition of the disease and prediction of response.[20]

The various biomarkers give similar diagnostic yields of around 25% in patients with functional bowel disorders with diarrhea.[21] In countries such as the US, where SeHCAT is not available, fecal bile acids and C4 are available to make the diagnosis.[21]

Classification

Bile acid malabsorption was first recognized in patients with ileal disease.[22] When other causes were recognized, and an idiopathic, primary form described,[23] a classification into three types was proposed:[24]

Treatment

Bile acid sequestrants are the main agents used to treat bile acid malabsorption.[25] Cholestyramine and colestipol, both in powder form, have been used for many years. Unfortunately, many patients find them difficult to tolerate; although the diarrhea may improve, other symptoms such as abdominal pain and bloating may worsen.

Colesevelam is a tablet which is well tolerated and has been shown in placebo-controlled, randomized clinical trials to be effective.[26] [27] [28] [29]

The farnesoid X receptor agonist obeticholic acid has shown clinical and biochemical benefits in a proof of concept study.[30] Tropifexor is another farnesoid X receptor agonist that has been studied, showing improvements in biochemistry and colonic transit.[31]

Liraglutide, a GLP-1 receptor agonist had unexpected effects in clinical cases with co-existing bile acid diarrhoea[32] which led to a randomised, double-blind, active-comparator, non-inferiority clinical trial.[33] This trial demonstrated superiority in favour of liraglutide compared with colesevelam in reducing stool frequency and improved pathophysiological markers, suggesting it may be a new, safe and more effective treatment compared with current established, cheaper treatment modalities.

Epidemiology

Bile acid malabsorption is common in Crohn's disease but not always recognized. Most people with previous ileal resection and chronic diarrhea will have abnormal SeHCAT tests and can benefit from bile acid sequestrants.

People with primary bile acid diarrhea are frequently misdiagnosed as having irritable bowel syndrome.[17] When SeHCAT testing is performed, the diagnosis of primary bile acid diarrhea is commonly made. In a review of 18 studies of the use of SeHCAT testing in diarrhea-predominant irritable bowel syndrome patients, 32% of 1223 people had a SeHCAT 7-day retention of less than 10%, and 80% of these reported a response to cholestyramine, a bile acid sequestrant.

A study from 2023 investigating the epidemiology of bile acid diarrhea in Denmark, found that people suffering from bile acid diarrhea seemed to have more co-morbidities, lower levels of income and education and more health care contacts compared with matches not suffering from bile acid diarrhea.[34]

Estimates of the population prevalence suggest that 1% of the adult population could have primary bile acid diarrhea (Type 2 bile acid malabsorption).

Notes and References

  1. Book: Zhang . Lizhi . Chandan . Vishal S. . Wu . Tsung-Teh . Surgical Pathology of Non-neoplastic Gastrointestinal Diseases . 2019 . Springer . 978-3-030-15573-5 . 226 . en.
  2. Vijayvargiya P, Camilleri M . Update on Bile Acid Malabsorption: Finally Ready for Prime Time? . Current Gastroenterology Reports . 20 . 3 . 10 . March 2018 . 29582208 . 10.1007/s11894-018-0615-z . 4419631 .
  3. Bannaga . A . Kelman . L . O'Connor . M . Pitchford . C . Walters . JR . Arasaradnam . RP . How bad is bile acid diarrhoea: an online survey of patient-reported symptoms and outcomes. . BMJ Open Gastroenterology . 2017 . 4 . 1 . e000116 . 10.1136/bmjgast-2016-000116 . 28123771. 5253456 . free .
  4. Sadowski . DC . Camilleri . M . Chey . WD . Leontiadis . GI . Marshall . JK . Shaffer . EA . Tse . F . Walters . JRF . Canadian Association of Gastroenterology Clinical Practice Guideline on the Management of Bile Acid Diarrhea. . Clinical Gastroenterology and Hepatology. January 2020 . 18 . 1 . 24–41.e1 . 10.1016/j.cgh.2019.08.062 . 31526844. free . 10044/1/76745 . free .
  5. Hofmann AF . Chronic diarrhea caused by idiopathic bile acid malabsorption: an explanation at last . Expert Review of Gastroenterology & Hepatology . 3 . 5 . 461–4 . October 2009 . 19817666 . 10.1586/egh.09.49 . free .
  6. Dawson. PA. Lan, T. Rao, A. Bile acid transporters. Journal of Lipid Research. 2009. 50. 12. 2340–57. 19498215. 10.1194/jlr.R900012-JLR200 . free . 2781307.
  7. Oelkers. P . Kirby, LC . Heubi, JE . Dawson, PA. Primary bile acid malabsorption caused by mutations in the ileal sodium-dependent bile acid transporter gene (SLC10A2). The Journal of Clinical Investigation. 1997. 99. 8. 1880–7. 9109432. 10.1172/JCI119355. 508012.
  8. Montagnani. M . Love, MW . Rössel, P . Dawson, PA . Qvist, P. Absence of dysfunctional ileal sodium-bile acid cotransporter gene mutations in patients with adult-onset idiopathic bile acid malabsorption. Scandinavian Journal of Gastroenterology. 2001. 36. 10. 1077–80. 11589382. 10.1080/003655201750422693. 218908622 .
  9. Walters. JR . Tasleem, AM . Omer, O S . Brydon, WG . Dew, T . le Roux, CW . A new mechanism for bile acid diarrhea: defective feedback inhibition of bile acid biosynthesis. Clinical Gastroenterology and Hepatology. 2009. 7. 11. 1189–94. 19426836. 10.1016/j.cgh.2009.04.024. free.
  10. van Tilburg. AJ . de Rooij, FW . van den Berg, JW . van Blankenstein, M . Primary bile acid malabsorption: a pathophysiologic and clinical entity?. Scandinavian Journal of Gastroenterology. Supplement. 1992. 194. 66–70. 1298051. 10.3109/00365529209096030 .
  11. Kårhus . ML . Enterohepatic, Gluco-metabolic, and Gut Microbial Characterization of Individuals With Bile Acid Malabsorption . Gastro Hep Advances . 2022 . 1 . 3 . 299-312 . 10.1016/j.gastha.2021.12.007. free .
  12. Kårhus . ML . Enterohepatic, Gluco-metabolic, and Gut Microbial Characterization of Individuals With Bile Acid Malabsorption . Gastro Hep Advances . 2022 . 1 . 3 . 299-312 . 10.1016/j.gastha.2021.12.007. free .
  13. Sagar . NM . The pathophysiology of bile acid diarrhoea: differences in the colonic microbiome, metabolome and bile acids . Sci Rep . November 2020 . 10 . 1 . 20436 . 10.1038/s41598-020-77374-7 . 33235223. 7686486 . 10044/1/87396 . free .
  14. Jeffery . IB . Differences in Fecal Microbiomes and Metabolomes of People With vs Without Irritable Bowel Syndrome and Bile Acid Malabsorption . Gastroenterology . March 2020 . 158 . 4 . 1016–1028.e8 . 10.1053/j.gastro.2019.11.301 . 31843589. free .
  15. Vijayvargiya P, Camilleri M, Shin A, Saenger A . Methods for diagnosis of bile acid malabsorption in clinical practice . Clin. Gastroenterol. Hepatol. . 11 . 10 . 1232–9 . 2013 . 23644387 . 3783593 . 10.1016/j.cgh.2013.04.029 .
  16. Wedlake L, A'Hern R, Russell D, Thomas K, Walters JR, Andreyev HJ . Systematic review: the prevalence of idiopathic bile acid malabsorption as diagnosed by SeHCAT scanning in patients with diarrhoea-predominant irritable bowel syndrome . Aliment. Pharmacol. Ther. . 30 . 7 . 707–17 . 2009 . 19570102 . 10.1111/j.1365-2036.2009.04081.x . 11327665 . free .
  17. Walters. JR. Defining primary bile acid diarrhea: making the diagnosis and recognizing the disorder. Expert Review of Gastroenterology & Hepatology. 2010. 4. 5. 561–7. 20932141. 10.1586/egh.10.54. 27123642.
  18. Khalid. U. Lalji, A. Stafferton, R. Andreyev, J. Bile acid malabsorption: a forgotten diagnosis?. . 2010. 10. 2. 124–6. 20437979. 10.7861/clinmedicine.10-2-124. 4952080.
  19. Brydon. WG. Nyhlin, H. Eastwood, MA. Merrick, MV. Serum 7 alpha-hydroxy-4-cholesten-3-one and selenohomocholyltaurine (SeHCAT) whole body retention in the assessment of bile acid induced diarrhoea. European Journal of Gastroenterology & Hepatology. 1996. 8. 2. 117–23. 8723414. 10.1097/00042737-199602000-00005. 23867181.
  20. Pattni SS, Brydon WG, Dew T, Johnston IM, Nolan JD, Srinivas M, Basumani P, Bardhan KD, Walters JR . Fibroblast growth factor 19 in patients with bile acid diarrhoea: a prospective comparison of FGF19 serum assay and SeHCAT retention . Aliment. Pharmacol. Ther. . 38 . 8 . 967–76 . 2013 . 23981126 . 10.1111/apt.12466 . 6386339 . free .
  21. Valentin. N. Camilleri. M. Altayar. O. Vijayvargiya. P. Acosta. A. Nelson. AD. Murad. MH. Biomarkers for bile acid diarrhoea in functional bowel disorder with diarrhoea: a systematic review and meta-analysis.. Gut. December 2016. 65. 12. 1951–1959. 10.1136/gutjnl-2015-309889. 26347530. 3454888.
  22. Hofmann. AF. The syndrome of ileal disease and the broken enterohepatic circulation: cholerheic enteropathy.. Gastroenterology. 1967. 52. 4. 752–7. 5337211. 10.1016/S0016-5085(67)80140-9. free.
  23. Thaysen. EH. Pedersen, L. Idiopathic bile acid catharsis.. Gut. 1976. 17. 12. 965–70. 1017717. 1411224. 10.1136/gut.17.12.965.
  24. Fromm. H. Malavolti, M. Bile acid-induced diarrhoea. Clinics in Gastroenterology. 1986. 15. 3. 567–82. 10.1016/S0300-5089(21)00739-2. 3742841.
  25. Wilcox C, Turner J, Green J . Systematic review: the management of chronic diarrhoea due to bile acid malabsorption . Aliment. Pharmacol. Ther. . 39 . 9 . 923–39 . May 2014 . 24602022 . 10.1111/apt.12684 . 12016216 . free .
  26. Wedlake. L. Thomas, K. Lalji, A. Anagnostopoulos, C. Andreyev, HJ. Effectiveness and tolerability of colesevelam hydrochloride for bile-acid malabsorption in patients with cancer: a retrospective chart review and patient questionnaire. Clinical Therapeutics. 2009. 31. 11. 2549–58. 20109999. 10.1016/j.clinthera.2009.11.027.
  27. Web site: NICE. Bile acid malabsorption: colesevelam. 29 October 2013 . 17 August 2014.
  28. Beigel F, Teich N, Howaldt S, Lammert F, Maul J, Breiteneicher S, Rust C, Göke B, Brand S, Ochsenkühn T . Colesevelam for the treatment of bile acid malabsorption-associated diarrhea in patients with Crohn's disease: A randomized, double-blind, placebo-controlled study . J Crohns Colitis . 8 . 11 . 1471–9 . November 2014 . 24953836 . 10.1016/j.crohns.2014.05.009 . free .
  29. Borup C, Vinter-Jensen L, Jørgensen SP, Wildt S, Graff J, Gregersen T, Zaremba A, Borup Andersen T, Nøjgaard C, Timm HB, Rainteau D, Hansen SH, Rumessen JJ, Munck LK . Efficacy and safety of colesevelam for the treatment of bile acid diarrhoea: a double-blind, randomised, placebo-controlled, phase 4 clinical trial . The Lancet. Gastroenterology & Hepatology . 8 . 4 . 321–331 . April 2023 . 36758570 . 10.1016/S2468-1253(22)00401-0 .
  30. Walters JR, Johnston IM, Nolan JD, Vassie C, Pruzanski ME, Shapiro DA . The response of patients with bile acid diarrhoea to the farnesoid X receptor agonist obeticholic acid . Aliment. Pharmacol. Ther. . 41 . 1 . 54–64 . January 2015 . 25329562 . 10.1111/apt.12999 . 10044/1/21617 . 44661338 . free .
  31. Camilleri M, Nord SL, Burton D, Oduyebo I, Zhang Y, Chen J, Im K, Bhad P, Badman MK, Sanders DS, Walters JR . Randomised clinical trial: significant biochemical and colonic transit effects of the farnesoid X receptor agonist tropifexor in patients with primary bile acid diarrhoea . Alimentary Pharmacology & Therapeutics . 52 . 5 . 808–820 . September 2020 . 32702169 . 10.1111/apt.15967 .
  32. Kårhus . M L . Brønden . A . Røder . M E . Remission of Bile Acid Malabsorption Symptoms Following Treatment With the Glucagon-Like Peptide 1 Receptor Agonist Liraglutide . Gastroenterology . Aug 2019 . 157 . 2 . 569–571 . 10.1053/j.gastro.2019.04.002 . 30965026.
  33. Kårhus ML, Brønden A, Forman JL, Haaber A, Knudsen E, Langholz E, Dragsted LO, Hansen SH, Krakauer M, Vilsbøll T, Sonne DP, Knop FK . Safety and efficacy of liraglutide versus colesevelam for the treatment of bile acid diarrhoea: a randomised, double-blind, active-comparator, non-inferiority clinical trial . The Lancet. Gastroenterology & Hepatology . 7 . 10 . 922–931 . October 2022 . 35868334 . 10.1016/S2468-1253(22)00198-4 .
  34. Kårhus . M L . Ellegaard . A . Winther-Jensen . M . The Epidemiology of Bile Acid Diarrhea in Denmark . Clin Epidemiol . Dec 2023 . 15 . 1173–1181 . 10.2147/CLEP.S442054 . free . 38089008. 10712339 .

This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article "Bile acid malabsorption".

Except where otherwise indicated, Everything.Explained.Today is © Copyright 2009-2024, A B Cryer, All Rights Reserved. Cookie policy.